title: Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.
abstract: Colorectal cancer (CRC) is one of the most common malignancies worldwide. The prognosis for this cancer is poor, and the development of novel biomarkers, particularly non-invasive surrogate biomarkers, is urgently needed. Recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in the blood and can serve as useful biomarkers for various types of cancer. In this study, the miR-183 expression levels were found to be significantly overexpressed in plasma samples from CRC patients compared with controls, and the postoperative plasma miR-183 levels were significantly reduced compared with the preoperative levels. The value of the area under the receiver operating characteristic (ROC) curve obtained for miR-183 was 0.829, which was higher than those for carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). High plasma miR-183 expression was significantly associated with lymph node metastasis, distant metastasis, higher pTNM stage (III-IV), and tumor recurrence. CRC patients with elevated miR-183 expression in plasma displayed shorter disease-free survival (DFS) and lower overall survival (OS). More importantly, plasma miR-183 was independently correlated with tumor recurrence and a lower OS. Collectively, our results suggested that the elevated miR-183 in the plasma could be a promising biomarker for predicting the risk of tumor recurrence and poor survival in CRC patients.
authors: a Department of Surgical Oncology ; First Affiliated Hospital of Xi'an Jiaotong University ; Xi'an , China.
authors: Dawei
authors: D
authors: Yuan
authors: Kang
authors: K
authors: Li
authors: Kun
authors: K
authors: Zhu
authors: Rong
authors: R
authors: Yan
authors: Chengxue
authors: C
authors: Dang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C533449:MIRN183 microRNA, human; D035683:MicroRNAs
keywords: AUC, area under curve; CA19–9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; DFS, disease-free survival; HR, hazard ratio; MiR-183; MiRNAs, microRNAs; MicroRNA; OS, overall survival; PCR, polymerase chain reaction; ROC, receiver operating characteristic; biomarker; colorectal cancer; pTNM, pathological tumor-node-metastasis; plasma; prognosis; recurrence
references: Clin Cancer Res. 2011 Jul 15;17(14):4772-81
references: 21622722
references: Cancer Cell. 2006 Mar;9(3):189-98
references: 16530703
references: Dig Dis Sci. 2014 May;59(5):911-9
references: 24337687
references: J Gastroenterol Hepatol. 2010 Oct;25(10):1674-80
references: 20880178
references: Am J Pathol. 2012 Jun;180(6):2440-51
references: 22525461
references: BMC Cancer. 2014;14:448
references: 24938880
references: Med Res Rev. 2012 Mar;32(2):326-48
references: 22383180
references: Cell Res. 2008 Oct;18(10):997-1006
references: 18766170
references: Front Genet. 2013 Jun 21;4:116
references: 23802013
references: Eur J Gastroenterol Hepatol. 2014 Feb;26(2):229-33
references: 24150523
references: Nature. 2005 Jun 9;435(7043):834-8
references: 15944708
references: Nat Rev Genet. 2009 Oct;10(10):704-14
references: 19763153
references: Cancer Prev Res (Phila). 2012 Mar;5(3):492-7
references: 22158052
references: Cancer Res. 2010 Dec 1;70(23):9570-80
references: 21118966
references: Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11831-6
references: 8876223
references: BMC Cancer. 2010;10:502
references: 20858276
references: Cell. 2004 Jan 23;116(2):281-97
references: 14744438
references: Cancer Gene Ther. 2006 Feb;13(2):115-24
references: 16138117
references: J Mol Diagn. 2010 Jul;12(4):433-40
references: 20413677
references: Gene. 2013 Sep 15;527(1):26-32
references: 23791657
references: Mol Diagn Ther. 2014 Jun;18(3):303-8
references: 24566942
references: Urology. 2011 May;77(5):1265.e9-16
references: 21539977
references: Ann Surg. 2014 Apr;259(4):735-43
references: 23982750
references: Gene. 2014 Jan 15;534(1):60-5
references: 24404590
references: PLoS One. 2008;3(11):e3694
references: 19002258
references: Nat Rev Cancer. 2006 Nov;6(11):857-66
references: 17060945
references: Evol Dev. 2008 Jan-Feb;10(1):106-13
references: 18184361
references: Int J Oncol. 2009 Apr;34(4):1069-75
references: 19287964
references: BMC Cancer. 2009;9:401
references: 19922656
references: Int J Biochem Cell Biol. 2013 Mar;45(3):536-45
references: 23262295
references: Cancer Res. 2005 Aug 15;65(16):7065-70
references: 16103053
references: PLoS One. 2011;6(3):e17745
references: 21445232
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5
references: 16737947
references: Cancer Lett. 2014 May 28;347(1):15-21
references: 24491406
references: Cancer Res. 2005 Jun 15;65(12):5133-43
references: 15958557
references: PLoS One. 2013;8(2):e56718
references: 23437222
references: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references: 18663219
references: Br J Cancer. 2011 Jun 28;105(1):104-11
references: 21673684